271 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
Rank Status Study
1 Available Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
Conditions: Bladder Cancer;   High Grade;   Non Muscle Invasive
Intervention: Biological: oncolytic adenovirus expressing GMCSF
2 Available Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders;   Pyruvate Carboxylase Deficiency, Type B;   Acyl-coA Dehydrogenase, Type 9
Intervention: Drug: triheptanoin
3 No longer available Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Condition: West Nile Virus Infection
Intervention: Biological: MGAWN1
4 No longer available Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver
Condition: Liver Diseases
Intervention: Drug: Defibrotide
5 Unknown  Second Line Therapy to Treat Age-Related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
Condition: Age Related Macular Degeneration
Interventions: Drug: Visudyne;   Drug: Lucentis;   Drug: Dexamethasone
6 Available Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: Stiripentol
7 Available An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Condition: Differentiated Thyroid Cancer
Intervention: Drug: Lenvatinib
8 No longer available Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Mycophenolic acid
9 Available Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
Condition: Byler Disease
Intervention: Drug: RAVICTI
10 Approved for marketing Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
Conditions: Cystic Fibrosis;   Pseudomonas Aeruginosa
Intervention: Drug: Aztreonam lysine
11 Approved for marketing Korean Early Access Program
Condition: Leukemia
Intervention: Drug: Dasatinib
12 Available Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
13 No longer available Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: nilotinib
14 Temporarily not available Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)
Condition: Pulmonary Embolism
Intervention: Drug: Gadofosveset Triodium
15 No longer available Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate
Condition: Macular Degeneration
Intervention: Drug: Anecortave Acetate
16 Approved for marketing TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
Condition: HIV Infections
Intervention: Drug: TMC-114
17 Available A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Daclatasvir (BMS-790052);   Drug: Sofosbuvir
18 No longer available A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: melphalan;   Drug: prednisone
19 Available Expanded Access Protocol of Blinatumomab in Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Blinatumomab
20 No longer available A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Open Label Treatment Access: Maraviroc

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years